07:00 , Jun 3, 2013 |  BioCentury  |  Product Development

The DMD landscape

Three companies are vying to gain the first approved drug for Duchenne muscular dystrophy in a race that has seen one company's stock soar 309% over the past year and the other two companies file...
08:00 , Jan 16, 2012 |  BC Week In Review  |  Company News

Tivorsan, Muscular Dystrophy Association musculoskeletal news

Tivorsan received $1 million from the association to accelerate preclinical development of TVN-102 to treat Duchenne muscular dystrophy (DMD). In October, Tivorsan and its academic collaborators received a $1.3 million award, which was part of...